Brief: BioArctic Says New Drug Application For Subcutaneous Formulation Of Leqembi Submitted In Japan
28/11/2025 05:31
Nov 28 (Reuters) - BioArctic AB BIOAb.ST: NEW DRUG APPLICATION FOR SUBCUTANEOUS FORMULATION OF LEQEMBI[®] SUBMITTED IN JAPAN BIOARCTIC AB - SIMILAR APPLICATION FOR SUBCUTANEOUS LECANEMAB SUBMITTED TO U.S. FDA Source text: ID:nWkr6cl6B6 Further company coverage: [BIOAb.ST] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln